One day after Bristol Myers Squibb announced the commercial launch of multiple sclerosis drug Zeposia (ozanimod), the company said the medication demonstrated statistically significant efficacy as a potential induction and maintenance therapy for ulcerative colitis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,